A Study in Evaluating Bioequivalence of Test and Reference Vadadustat 450 MG and 150 MG Tablets and to Determine Food Effect on the 450 MG Tablet
- Registration Number
- NCT03657290
- Lead Sponsor
- Akebia Therapeutics
- Brief Summary
This is a healthy volunteers study to assess the bioequivalence of vadadustat 450 mg tablets (Test A) compared to three 150mg tablets (Reference B). The study will also assess the effect of food on the bioavailability of vadadustat 450 mg tablet.
- Detailed Description
This is a randomized, open-label, single-dose, three-period crossover study in healthy adults to assess the bioequivalence of 3 X 150 mg vadadustat tablets (Test) compared to a single 450 mg vadadustat tablet (reference). Blood samples for vadadustat PK will be collected at pre-dose (0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 9, 12, 18, 24, 32, 40, and 48 hours post-dose. The study will also assess the effect of food on vadadustat bioavailability by evaluating the pharmacokinetics of the 450 mg tablet in fed and fasted subjects.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 54
Inclusion Criteria
- Male or female subjects between ≥18 years and ≤55 years of age
- Healthy subjects per Investigator judgment as documented by the medical history, physical examination, vital sign assessments, 12-lead electrocardiogram (ECG), clinical laboratory assessments, and general observations.
- Have a body weight ≥50 kg and body mass index (BMI) ≥18.5 kg/m2 to 29.5 kg/m2 inclusive
- Understands the procedures, provides ICF and willing to comply with study requirements
- Willing and able to comply with the requirements of the study protocol.
Exclusion Criteria
- Current or past history of cardiovascular, cerebrovascular, pulmonary, gastrointestinal, hematologic, renal, hepatic, immunologic, metabolic, urologic, neurologic, dermatologic, psychiatric, or other major disease.
- History of cancer (except non- melanoma skin cancer) or history of chemotherapy use.
- Any surgical or medical condition or history that may potentially alter the absorption, metabolism, or excretion of study treatment, such as, but not limited to gastric bypass surgery or gastric or duodenal ulcers.
- History of severe allergic or anaphylactic reactions. Chronic daily medication use.
- History of drug abuse Excessive alcohol consumption.
- Smoking and the use of nicotine-containing products
- Consumption of grapefruit or grapefruit juice, pomelo, star fruit, Seville or Moro (blood) orange, or their associated products
- Participation in another clinical trial or exposure to any investigational agent.
- Donation of blood or significant blood loss or plasma donation.
- Any condition that would interfere with the ability to provide informed consent, comply with study instructions, or which might confound the interpretation of the study results or put the patient at undue risk.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Treatment B vadadustat Vadadustat 1 X 450 mg Tablets in fasted subjects Treatment C vadadustat vadadustat 1 X 450 mg Tablets in fed subjects Treatment A vadadustat vadadustat 3 X 150 mg Tablets in fasted subjects
- Primary Outcome Measures
Name Time Method Bioequivalence - Area under plasma concentration-time curve from 0 to last quantifiable concentration (AUClast) Baseline visit, 48 hours Bioequivalence - Observed Maximum concentration (Cmax) Baseline visit, 48 hours Bioequivalence - Area under plasma concentration-time curve from 0 to infinity (AUCinf) Baseline visit, 48 hours Measure Food Effect - Area under plasma concentration-time curve from 0 to last quantifiable concentration (AUClast) Baseline visit, 48 hours Measure Food Effect - 2. Area under plasma concentration-time curve from 0 to infinity (AUCinf) Baseline visit, 48 hours Measure Food Effect - 2.3. Observed Maximum concentration (Cmax) Baseline visit, 48 hours Bioequivalence - Area under plasma concentration-time curve from 0 to last sampling point (AUCall) Baseline visit, 48 hours
- Secondary Outcome Measures
Name Time Method Apparent total body clearance (CL/F) Baseline visit, 48 hours Time to reach Cmax Baseline visit, 48 hours Elimination rate constant (Kel) Baseline visit, 48 hours Apparent volume of distribution (Vd/F) Baseline visit, 48 hours Mean residence time (MRT) Baseline visit, 48 hours Percentage of extrapolated area under the curve from time t to infinity (AUCextrap or Residual Area) Baseline visit, 48 hours Terminal half-life (t1/2) Baseline visit, 48 hours Time to reach Tmax Baseline visit, 48 hours
Trial Locations
- Locations (1)
Paraxel International
🇺🇸Baltimore, Maryland, United States